BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

Cathal Strain

President at Neo PLM    


Cathal founded Neo PLM following a career at Pfizer that spanned nearly 32 years. During that time, he gained considerable hands-on experience in manufacturing, both in high-volume continuous manufacturing and complex multi-product batch environments. He led the design, commissioning and startup of several new and highly automated multi-product plants as well as the retrofitting of many older facilities. With a deep understanding of the challenges of manufacturing, Cathal increasingly focused on technology as his career progressed and became a leader in the application of advanced and innovative technologies at Pfizer’s API manufacturing plants. He pioneered the implementation of one of the pharmaceutical industry’s first fully electronic batch record systems, and following that he led the envisioning, development and deployment of the world’s first integrated PLM solution for process manufacturing. This technology received the Microsoft Innovation Award for Manufacturing.

Cathal strongly believes that PLM for process manufacturers, centered around digital design, will usher in a new era—driving benefits similar to those experienced by discrete manufacturers using CAD-based PLM.

Contributing Author   in
Manufacturing & Pharma 4.0  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Latest articles from Cathal


Paving A Pathway To Pharma 4.0

Feb. 21, 2020   
Paving A Pathway To Pharma 4.0

Pharmaceutical manufacturers find themselves at a critical juncture. In the past 30 years, pharma has seen some significant shifts. Consider the expanding range of drug therapies, once confined almost exclusively to small molecule drugs. Biologics now comprise a substantial share …

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.